PoliticalAction.com Blog

It all started in the 1920’s with Yellow Journalism.

William Randolph Hearst, who arrived on the scene in 1887, was already in control of the headlines on a day-to-day basis because of his efficient business practice within the industry. He was able to produce his Newspapers at next to nothing by manufacturing the tree pulp used and controlling the channel of production down to his papers, the San Francisco Examiner, and eventually the New York Journal (Which became a leading Newspaper).

He teamed up with Henry Dupont to manufacture the ink used in the New York Journal and the partnership began to grow.

ALONG CAME HEMP

Hemp grows 4 times faster than the timber used for tree pulp by Hearst.

Hemp grows annually and can be grown more times

Hemp produces a better quality paper.

Hemp can be grown in any region of the United States.

Since Hemp grew so fast and it grew in every region, Hearst could not stop the middle class farmer from decentralizing the industry. Hearst knew that he could not provide the intellectual property to keep Hemp from destroying his industry and replacing it with middle class producers

In other words he was afraid of the free market. He was afraid of us… he had to stop it!

Dupont and Hearst knew then that not many Americans understood the difference between Hemp and Cannabis. So they used it against the Americans by claiming Cannabis will make you rape and kill your sister if smoked, illustrating the dangers of inhaling by using grim reapers in their newspapers with joints. And people believed it!

Time and Time again they would use this propaganda through the New York Journal, claiming that Mexicans bringing Marijuana across the border would sleep with White Wives and take White Jobs. They were also saying this about Black Americans who took up smoking and started the Jazz movement.

Dupont’s banker was Andrew Mellon, Mellon bank of Pittsburgh (5th largest bank at the time). Andrew Mellon had a Nephew, Harry Anslinger. Andrew Mellon financially backed Anslinger and threw all of his weight into convincing the U.S. treasury that Marijuana is dangerous and it should be heavily regulated by way of taxation and prohibition.

The treasury could use a program that would generate that much income for the government so in June of 1930 the treasury gave birth to the Federal Bureau of Narcotics.

Ansligner hated Mexicans, Blacks, and Cannabis. He was on a mission to eliminate all of them. Immediately Ansliger waged war on Cannabis regurgitating claims made by Hearst in his Newspapers. (Success stories followed in the New York Journal).

Then, in 1937 Anslinger approached congress with intent to fully regulate all Cannabis. The entire meeting was comprised of Ansliger making emotional outbursts and attempting to offer evidence, all of which was newspaper clippings out of Hearst’s Newspapers.

With the exception of one congressman, all agreed and the act passed, Marijuana became criminal giving birth to the Drug War.

Not to mention Hearst, Dupont, and Mellon were all filthy rich now and had their hands in official pockets.

But the story doesn’t stop here. Andrew Mellon had to study the enemy, He saw what happened with Alcohol Prohibition and he knew it wouldn’t be long before the public caught on.

Mr. Mellon then financed Pharmaceutical companies through government grants and private equity to try to create a synthetic substitute for the over 60 different medicinal properties Cannabis contains. (They have yet to accomplish this goal)

If you look into the history you will find that fossil fuels would have never existed if it wasn’t for this intervention in the market place.

CANNABIS CAN SUPPLY THE ENTIRE NATION WITH ENERGY ON ONLY 1% OF U.S. LAND. ALL CARBON CLEAN.

(AND REMEMBER IT GROWS EVERYWHERE)

This is where the Federal Reserve comes in. The Federal Reserve System does not want to see the decentralization of resources towards localism because if that were to happen the Fed would lose a stronghold on the liquidity pools it artificially creates. It would also mean they couldn’t use the Carbon Tax to consolidate wealth across the world.

With Cannabis being legal and having over 25,000 uses there would be no way to compete against local and more sustainable banks.

So, the Federal Reserve uses banks like the Mellon to fund the DEA and keep money flowing and keep marijuana illegal. The Fed knows that with Cannabis being legal our GDP would boom but not in favor of large monopolies like the FED, but quite the contrary.

This is why I always say… the day we legalize it is the day we end the FED!

By Americans for Safe Access, Medical Marijuana Therapeutics/Research

HOUSTON — The American Medical Association (AMA) voted today to reverse its long-held position that marijuana be retained as a Schedule I substance with no medical value. The AMA adopted a report drafted by the AMA Council on Science and Public Health (CSAPH) entitled, “Use of Cannabis for Medicinal Purposes,” which affirmed the therapeutic benefits of marijuana and called for further research. The CSAPH report concluded that, “short term controlled trials indicate that smoked cannabis reduces neuropathic pain, improves appetite and caloric intake especially in patients with reduced muscle mass, and may relieve spasticity and pain in patients with multiple sclerosis.” Furthermore, the report urges that “the Schedule I status of marijuana be reviewed with the goal of facilitating clinical research and development of cannabinoid-based medicines, and alternate delivery methods.”

The change of position by the largest physician-based group in the country was precipitated in part by a resolution adopted in June of 2008 by the Medical Student Section (MSS) of the AMA in support of the reclassification of marijuana’s status as a Schedule I substance. In the past year, the AMA has considered three resolutions dealing with medical marijuana, which also helped to influence the report and its recommendations. The AMA vote on the report took place in Houston, Texas during the organization’s annual Interim Meeting of the House of Delegates. The last AMA position, adopted 8 years ago, called for maintaining marijuana as a Schedule I substance, with no medical value.

“It’s been 72 years since the AMA has officially recognized that marijuana has both already-demonstrated and future-promising medical utility,” said Sunil Aggarwal, Ph.D., the medical student who spearheaded both the passage of the June 2008 resolution by the MSS and one of the CSAPH report’s designated expert reviewers. “The AMA has written an extensive, well-documented, evidence-based report that they are seeking to publish in a peer-reviewed journal that will help to educate the medical community about the scientific basis of botanical cannabis-based medicines.” Aggarwal is also on the Medical & Scientific Advisory Board of Americans for Safe Access (ASA), the largest medical marijuana advocacy organization in the U.S.

The AMA’s about face on medical marijuana follows an announcement by the Obama Administration in October discouraging U.S. Attorneys from taking enforcement actions in medical marijuana states. In February 2008, a resolution was adopted by the American College of Physicians (ACP), the country’s second largest physician group and the largest organization of doctors of internal medicine. The ACP resolution called for an “evidence-based review of marijuana’s status as a Schedule I controlled substance to determine whether it should be reclassified to a different schedule. “The two largest physician groups in the U.S. have established medical marijuana as a health care issue that must be addressed,” said ASA Government Affairs Director Caren Woodson. “Both organizations have underscored the need for change by placing patients above politics.”

Though the CSAPH report has not been officially released to the public, AMA documentation indicates that it: “(1) provides a brief historical perspective on the use of cannabis as medicine; (2) examines the current federal and state-based legal envelope relevant to the medical use of cannabis; (3) provides a brief overview of our current understanding of the pharmacology and physiology of the endocannabinoid system; (4) reviews clinical trials on the relative safety and efficacy of smoked cannabis and botanical-based products; and (5) places this information in perspective with respect to the current drug regulatory framework.”